MA25351A1 - Nouvelle methode de traitement - Google Patents

Nouvelle methode de traitement

Info

Publication number: MA25351A1
Authority: MA; Morocco
Prior art keywords: processing method; new processing; new; processing
Prior art date: 1999-04-15

Application number

MA26355A

Other languages

English (en)

Inventor

Colin Houston Macphee

Original Assignee

Smithkline Beecham Plc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-04-15

Filing date

2001-10-12

Publication date

2001-12-31

2001-10-12 Application filed by Smithkline Beecham Plc filed Critical Smithkline Beecham Plc

2001-12-31 Publication of MA25351A1 publication Critical patent/MA25351A1/fr

Links

238000003672 processing method Methods 0.000 title 1

Classifications

- G—PHYSICS
- G11—INFORMATION STORAGE
- G11B—INFORMATION STORAGE BASED ON RELATIVE MOVEMENT BETWEEN RECORD CARRIER AND TRANSDUCER
- G11B20/00—Signal processing not specific to the method of recording or reproducing; Circuits therefor
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/08—Antiseborrheics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/16—Emollients or protectives, e.g. against radiation
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/08—Antibacterial agents for leprosy
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Dermatology (AREA)
Physical Education & Sports Medicine (AREA)
Pulmonology (AREA)
Epidemiology (AREA)
Immunology (AREA)
Diabetes (AREA)
Orthopedic Medicine & Surgery (AREA)
Oncology (AREA)
Hematology (AREA)
Neurology (AREA)
Rheumatology (AREA)
Endocrinology (AREA)
Virology (AREA)
Urology & Nephrology (AREA)
Communicable Diseases (AREA)
Cardiology (AREA)
Toxicology (AREA)
Tropical Medicine & Parasitology (AREA)
Pain & Pain Management (AREA)
Emergency Medicine (AREA)
Ophthalmology & Optometry (AREA)
Biomedical Technology (AREA)
Heart & Thoracic Surgery (AREA)
Neurosurgery (AREA)
Obesity (AREA)

MA26355A 1999-04-15 2001-10-12 Nouvelle methode de traitement MA25351A1 (fr)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
GBGB9908647.2A GB9908647D0 (en)	1999-04-15	1999-04-15	Novel compounds

Publications (1)

Publication Number	Publication Date
MA25351A1 true MA25351A1 (fr)	2001-12-31

Family

ID=10851605

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
MA26355A MA25351A1 (fr)	1999-04-15	2001-10-12	Nouvelle methode de traitement

Country Status (32)

Country	Link
EP (2)	EP1593379A3 (fr)
JP (1)	JP2003516310A (fr)
KR (1)	KR20010108506A (fr)
CN (1)	CN1413105A (fr)
AP (1)	AP2001002291A0 (fr)
AT (1)	ATE319437T1 (fr)
AU (1)	AU4583000A (fr)
BG (1)	BG106104A (fr)
BR (1)	BR0009776A (fr)
CA (1)	CA2370127A1 (fr)
CZ (1)	CZ20013688A3 (fr)
DE (1)	DE60026508T2 (fr)
DK (1)	DK1274407T3 (fr)
DZ (1)	DZ3151A1 (fr)
EA (1)	EA200101089A1 (fr)
ES (1)	ES2256003T3 (fr)
GB (1)	GB9908647D0 (fr)
HK (1)	HK1053788A1 (fr)
HR (1)	HRP20010746A2 (fr)
HU (1)	HUP0300479A2 (fr)
ID (1)	ID30339A (fr)
IL (1)	IL145875A0 (fr)
MA (1)	MA25351A1 (fr)
MX (1)	MXPA01010428A (fr)
NO (1)	NO20014950L (fr)
PL (1)	PL364720A1 (fr)
PT (1)	PT1274407E (fr)
SK (1)	SK14532001A3 (fr)
TR (1)	TR200102977T2 (fr)
WO (1)	WO2000062766A2 (fr)
YU (1)	YU77901A (fr)
ZA (1)	ZA200108446B (fr)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB9913782D0 (en) *	1999-06-14	1999-08-11	Smithkline Beecham Plc	Novel compounds
AU2001223488A1 (en) *	2000-11-09	2002-05-21	Phenion Gmbh And Co. Kg	Activators of peroxisome proliferator-activated alpha and beta receptors as medicaments for treating skin disorders having immunological causes
GB0030845D0 (en) *	2000-12-18	2001-01-31	Smithkline Beecham Plc	Novel treatment
GB2373725A (en) *	2001-03-30	2002-10-02	Novartis Ag	Use of a PPAR gamma agonist in the production of a medicament for the prevention or treatment of diseases associated with IL-10 production
EP1465622A1 (fr) *	2001-11-26	2004-10-13	Arachnova Therapeutics Ltd.	Utilisation d'activateurs des ppar dans le traitement de fibrose pulmonaire
DE10204398A1 (de) *	2002-02-04	2003-08-14	Univ Goettingen Georg August	Neue Verwendung von Liganden der 'Peroxisome Proliferator-Activated receptors'(PPAR)
US6992093B2 (en)	2002-05-02	2006-01-31	Los Angeles Biomedical Research Institute At Harbor Ucla Medical Center	Method of inhibiting lipofibroblast to myofibroblast transdifferentiation
US8293479B2 (en)	2002-05-02	2012-10-23	Los Angeles Biomedical Research Institute At Harbor Ucla Medical Center	Use of parathyroid hormone-related protein(PTHRP) in the diagnosis and treatment of chronic lung disease and other pathologies
US20030220300A1 (en) *	2002-05-14	2003-11-27	Hwang Cheng Shine	Reduction of hair growth
ITRM20050389A1 (it)	2005-07-22	2007-01-23	Giuliani Spa	Composti e loro sali specifici per i recettori ppar ed i recettori per l'egf e loro uso in campo medico.
KR101333089B1 (ko)	2006-05-22	2013-11-27	재단법인 아산사회복지재단	로지글리타존을 유효성분으로 함유하는 흡연-유발 만성폐쇄성 폐질환 예방 또는 치료용 약제학적 조성물
ES2399179T3 (es) *	2008-08-07	2013-03-26	Pulmagen Therapeutics (Inflammation) Limited	Tratamiento de enfermedad respiratoria
US8236786B2 (en)	2008-08-07	2012-08-07	Pulmagen Therapeutics (Inflammation) Limited	Respiratory disease treatment
GB0913672D0 (en)	2009-08-05	2009-09-16	Argenta Discovery Ltd	Glitazones
UA107562C2 (uk)	2008-12-05	2015-01-26		Спосіб лікування псоріазу
EP2379507B1 (fr)	2008-12-30	2013-10-16	Pulmagen Therapeutics (Inflammation) Limited	Composés de sulfonamide pour le traitement de troubles respiratoires
HRP20170936T1 (hr)	2009-02-16	2017-09-22	Nogra Pharma Limited	Alkilamido spojevi i njihova uporaba
WO2010150014A1 (fr)	2009-06-24	2010-12-29	Pulmagen Therapeutics (Inflammation) Limited	Glitazones 5r-5–deutérés pour le traitement de maladies respiratoires
WO2011098746A1 (fr)	2010-02-09	2011-08-18	Pulmagen Therapeutics (Inflammation) Limited	Sels d'addition acide cristallins de l'énantiomère (5r) de la pioglitazone
GB201002243D0 (en)	2010-02-10	2010-03-31	Argenta Therapeutics Ltd	Respiratory disease treatment
GB201002224D0 (en)	2010-02-10	2010-03-31	Argenta Therapeutics Ltd	Respiratory disease treatment
WO2013117744A2 (fr)	2012-02-09	2013-08-15	Nogra Pharma Limited	Méthodes de traitement de la fibrose
NZ631049A (en)	2012-04-18	2017-02-24	Nogra Pharma Ltd	Methods of treating lactose intolerance
EP3191095A2 (fr) *	2014-09-08	2017-07-19	Dana Farber Cancer Institute, Inc.	Méthodes de traitement du cancer
KR20190095372A (ko) *	2017-01-13	2019-08-14	토비시 파마슈티칼 컴패니 리미티드	호중구 활성화 조절제
AU2020217884B2 (en)	2019-02-08	2025-02-20	Nogra Pharma Limited	Process of making 3-(4'-aminophenyl)-2-methoxypropionic acid, and analogs and intermediates thereof
JP2020145939A (ja) *	2019-03-12	2020-09-17	日本製粉株式会社	アレルギー性鼻炎抑制用組成物
CN116531374A (zh) *	2023-04-20	2023-08-04	中国医学科学院皮肤病医院(中国医学科学院皮肤病研究所)	吡格列酮及其盐在制备用于治疗系统性红斑狼疮的产品中的应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB9611947D0 (en) *	1996-06-07	1996-08-07	Glaxo Group Ltd	Medicaments
JPH10139665A (ja) *	1996-09-12	1998-05-26	Sankyo Co Ltd	トログリタゾンを含有するグルタチオン還元酵素活性増強剤
ATE462433T1 (de) *	1996-12-11	2010-04-15	Dana Farber Cancer Inst Inc	Methoden und pharmazeutische zusammensetzungen zur inhibition des tumorwachstums
US6646008B1 (en) *	1996-12-31	2003-11-11	The Salk Institute For Biological Studies	Treatment of disease states which result from neoplastic cell proliferation using PPAR-γ activators and compositions useful therefor
FR2773075B1 (fr) *	1997-12-31	2000-05-05	Cird Galderma	Utilisation d'activateurs de ppar-gamma en dermatologie
US6028088A (en) *	1998-10-30	2000-02-22	The University Of Mississippi	Flavonoid derivatives

1999
- 1999-04-15 GB GBGB9908647.2A patent/GB9908647D0/en not_active Ceased
2000
- 2000-04-11 DZ DZ003151A patent/DZ3151A1/fr active
- 2000-04-17 AT AT00927425T patent/ATE319437T1/de not_active IP Right Cessation
- 2000-04-17 HR HR20010746A patent/HRP20010746A2/hr not_active Application Discontinuation
- 2000-04-17 TR TR2001/02977T patent/TR200102977T2/xx unknown
- 2000-04-17 CA CA002370127A patent/CA2370127A1/fr not_active Abandoned
- 2000-04-17 EA EA200101089A patent/EA200101089A1/ru unknown
- 2000-04-17 IL IL14587500A patent/IL145875A0/xx unknown
- 2000-04-17 CN CN00809014A patent/CN1413105A/zh active Pending
- 2000-04-17 WO PCT/GB2000/001499 patent/WO2000062766A2/fr not_active Ceased
- 2000-04-17 MX MXPA01010428A patent/MXPA01010428A/es unknown
- 2000-04-17 HK HK03104497.7A patent/HK1053788A1/zh unknown
- 2000-04-17 JP JP2000611903A patent/JP2003516310A/ja active Pending
- 2000-04-17 KR KR1020017013106A patent/KR20010108506A/ko not_active Ceased
- 2000-04-17 DK DK00927425T patent/DK1274407T3/da active
- 2000-04-17 CZ CZ20013688A patent/CZ20013688A3/cs unknown
- 2000-04-17 BR BR0009776-4A patent/BR0009776A/pt not_active IP Right Cessation
- 2000-04-17 PT PT00927425T patent/PT1274407E/pt unknown
- 2000-04-17 EP EP05076787A patent/EP1593379A3/fr not_active Withdrawn
- 2000-04-17 AU AU45830/00A patent/AU4583000A/en not_active Abandoned
- 2000-04-17 YU YU77901A patent/YU77901A/sh unknown
- 2000-04-17 HU HU0300479A patent/HUP0300479A2/hu unknown
- 2000-04-17 AP APAP/P/2001/002291A patent/AP2001002291A0/en unknown
- 2000-04-17 ES ES00927425T patent/ES2256003T3/es not_active Expired - Lifetime
- 2000-04-17 ID IDW00200102237A patent/ID30339A/id unknown
- 2000-04-17 SK SK1453-2001A patent/SK14532001A3/sk unknown
- 2000-04-17 PL PL00364720A patent/PL364720A1/xx not_active Application Discontinuation
- 2000-04-17 DE DE60026508T patent/DE60026508T2/de not_active Expired - Lifetime
- 2000-04-17 EP EP00927425A patent/EP1274407B1/fr not_active Expired - Lifetime
2001
- 2001-10-11 NO NO20014950A patent/NO20014950L/no not_active Application Discontinuation
- 2001-10-12 MA MA26355A patent/MA25351A1/fr unknown
- 2001-10-15 ZA ZA200108446A patent/ZA200108446B/xx unknown
- 2001-11-13 BG BG106104A patent/BG106104A/xx unknown

Also Published As

Publication number	Publication date
HK1053788A1 (zh)	2003-11-07
DK1274407T3 (da)	2006-06-26
DZ3151A1 (fr)	2000-10-19
BR0009776A (pt)	2002-06-04
CA2370127A1 (fr)	2000-10-26
MXPA01010428A (es)	2002-05-06
NO20014950D0 (no)	2001-10-11
CN1413105A (zh)	2003-04-23
AU4583000A (en)	2000-11-02
EP1593379A2 (fr)	2005-11-09
SK14532001A3 (sk)	2002-02-05
HRP20010746A2 (en)	2002-10-31
GB9908647D0 (en)	1999-06-09
DE60026508D1 (de)	2006-05-04
DE60026508T2 (de)	2006-11-16
PT1274407E (pt)	2006-06-30
NO20014950L (no)	2001-12-13
YU77901A (sh)	2005-07-19
TR200102977T2 (tr)	2002-09-23
JP2003516310A (ja)	2003-05-13
EA200101089A1 (ru)	2002-10-31
WO2000062766A3 (fr)	2002-10-31
ZA200108446B (en)	2003-08-27
ATE319437T1 (de)	2006-03-15
HUP0300479A2 (hu)	2003-07-28
AP2001002291A0 (en)	2001-12-31
BG106104A (en)	2002-05-31
EP1274407A2 (fr)	2003-01-15
ES2256003T3 (es)	2006-07-16
CZ20013688A3 (cs)	2003-03-12
KR20010108506A (ko)	2001-12-07
WO2000062766A2 (fr)	2000-10-26
IL145875A0 (en)	2002-07-25
EP1593379A3 (fr)	2007-10-31
EP1274407B1 (fr)	2006-03-08
ID30339A (id)	2001-11-22
PL364720A1 (en)	2004-12-13

Publication	Publication Date	Title
MA25352A1 (fr)	2001-12-31	Nouvelle methode de traitement
MA25351A1 (fr)	2001-12-31	Nouvelle methode de traitement
EP1358650A4 (fr)	2008-03-19	Procede de traitement multimodal
EP1393708A4 (fr)	2010-02-17	Procede de traitement des cheveux
EP1423811A4 (fr)	2005-08-24	Traitement de transaction
FR2814945B1 (fr)	2003-02-14	Procede de traitement de la canitie
EP1100119A4 (fr)	2003-05-07	Procede de traitement au plasma
EP1332349A4 (fr)	2008-12-17	Systeme de traitement automatise
DE60022860D1 (de)	2005-11-03	Waferbearbeitungssystem
DE60138995D1 (de)	2009-07-30	Betrugssicheres Verarbeitungsverfahren
FI991186L (fi)	2000-11-26	Menetelmä ternimaidon käsittelemiseksi
DE60215096D1 (de)	2006-11-16	Optisches Verarbeitungssystem
FI991220L (fi)	2000-11-29	Menetelmä massan käsittelemiseksi
EP1366858A4 (fr)	2006-03-15	Polisseuse et procede de polissage
FR2788234B1 (fr)	2004-12-17	Procede de chanfreinage
PT1278816E (pt)	2006-08-31	Metodo para processar azeitonas
DE60033589D1 (de)	2007-04-12	Bildverarbeitung
EP1422743A4 (fr)	2006-04-05	Systeme de traitement
DE60213924D1 (de)	2006-09-28	Bildverarbeitungsverfahren
MA25522A1 (fr)	2002-10-01	Procede de traitement de copd
DE10194962T1 (de)	2003-12-04	Bildverarbeitungsverfahren
EP1389105A4 (fr)	2005-08-17	Methode de traitement
EP1282411A4 (fr)	2008-05-21	Methode de traitement anticancereux
EP0997450A4 (fr)	2000-10-04	PROCEDE DE REDUCTION DE NO x
DE60005700D1 (de)	2003-11-06	Fadenverarbeitungssystem